Will Gilead enter the autoimmune diseases market? - Korea Biomedical Review

Will Gilead enter the autoimmune diseases market?  Korea Biomedical Review

Gilead Sciences is highly likely to buy Otezla (apremilast), a new oral PDE4 inhibitor which BMS had secured by acquiring Celgene and later decided to sell, ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases